Volume 11, Number 2—February 2005
Perspective
Managing Febrile Respiratory Illnesses during Hypothetical SARS Outbreaks
, Peter Muennig†, Michael Gardam‡, and Joshua Graff Zivin†
Table 1
Selected costs in the decision-analysis model*
| Costs† | Low | Base | High | Source |
|---|---|---|---|---|
| Vaccines and medications | ||||
| Influenza vaccine | $10.00 | $27.78 | $40.00 | 11 |
| Antibiotics for FRI‡ | $30.00 | $64.72 | $80.00 | 12 |
| Medical care§ | ||||
| Ambulatory clinic visit | $40.00 | $60.03 | $80.00 | 13 |
| Hospitalization for FRI | $5,000 | $11,645 | $15,000 | 14 |
| Hospitalization for influenza | $7,500 | $17,465 | $25,000 | 14 |
| Hospitalization for PUI | $15,000 | $19,441 | $25,000 | 14 |
| Hospitalization for SARS | $20,000 | $28,502 | $40,000 | 14,15 |
| Diagnostic tests | ||||
| Rapid influenza test | $15.00 | $26.86 | $40.00 | 16 |
| Multiplex¶ RT-PCR | $50.00 | $154.02 | $200.00 | Prodesse Inc., pers. comm. |
| SARS# RT-PCR | $20.00 | $54.80 | $100.00 | Prodesse Inc., pers. comm. |
| Miscellaneous | ||||
| Patient time (per hour) | $15.00 | $24.55 | $30.00 | 17 |
| Contact investigation (per SARS contact) | $100.00 | $222.94 | $300.00 | 5,18 |
*FRI, febrile respiratory illness; PUI, person under investigation (for SARS); SARS, severe acute respiratory syndrome; RT-PCR, reverse transcription–polymerase chain reaction.
†Medical and nonmedical costs were adjusted to 2004 U.S. dollars by using the Consumer Price Index.
‡Antimicrobial drug costs are based on a 7-day course of oral levofloxacin.
§Includes laboratory tests, transportation costs, and patient time.
¶Detects influenza viruses A and B, respiratory syncytial viruses A and B, parainfluenza viruses 1–3, human metapneumovirus, Legionella pneumophila, L. micdadei, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis.
#Detects SARS-associated coronavirus and coronaviruses OC43 and 229E.